Investing.com - SAB Biotherapeutics (NASDAQ: SABS) reported second quarter EPS of $-0.140, in line with the analyst estimate of $-0.140. Revenue for the quarter came in at $200K versus the consensus estimate of $400K.
SAB Biotherapeutics's stock price closed at $0.760. It is down -10.590% in the last 3 months and down -28.080% in the last 12 months.
SAB Biotherapeutics saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See SAB Biotherapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, SAB Biotherapeutics's Financial Health score is "fair performance".
Check out SAB Biotherapeutics's recent earnings performance, and SAB Biotherapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar